Company News

Published 21-11-2025, 06:16 pm

Moligo and Cellectis show promise in non-viral gene editing method

Moligo and Cellectis show promise in non-viral gene editing method

ALCLS

-4.42%

STOCKHOLM - Moligo Technologies and Cellectis have demonstrated a potentially more efficient method for gene insertion in hematopoietic stem and progenitor cells (HSPCs) using enzymatically synthesized single-stranded DNA, according to a study published in Nature Communications on Friday. Cellectis (ALCLS), whose stock has surged over 26% in the past week and 151% over the last year according to InvestingPro data, continues to make strides in gene-editing technology despite not yet achieving profitability.

The research shows that Moligo’s enzymatically produced single-stranded DNA (ssDNA) vectors can achieve high knock-in efficiency in HSPCs, with circular ssDNA format demonstrating 3-5 times greater efficiency than linear formats.

The study addresses limitations of current gene therapy methods. Viral vectors, while effective, raise concerns about safety, efficacy, and cost. Previous non-viral DNA template delivery methods were limited to short DNA templates, primarily supporting gene correction rather than insertion.

According to the published findings, the ssDNA vectors can insert genes at multiple locations in HSPCs and can be applied to other therapeutically relevant cell types, including primary T cells. The research also indicated that HSPCs edited with circular ssDNA showed greater capacity to engraft and retain gene edits in murine models compared to those edited using AAV6. With a market capitalization of $355 million and impressive revenue growth of 129% in the last twelve months, Cellectis appears to be gaining traction in the biotech space. Analysts have set a target price of $7.50, suggesting significant upside potential from current levels, though InvestingPro data indicates the stock is slightly overvalued compared to its Fair Value. Subscribers can access the comprehensive Pro Research Report covering Cellectis among 1,400+ US equities.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

"This study provides clear evidence that Moligo’s enzymatically produced long ssDNA vectors can serve as a robust, scalable alternative to viral delivery," said Moligo CEO Cosimo Ducani in the press release.

Julien Valton, Vice President of Gene Therapy at Cellectis, stated that the results "establish the CssDNA and TALEN editing process as an efficient non-viral gene insertion strategy and mark a pivotal advance towards the development of next-generation cell and gene therapies."

The collaboration between Moligo, which specializes in DNA synthesis, and Cellectis, a clinical-stage biotechnology company focused on gene-editing platforms, aims to advance safer and more effective gene-based therapeutics.

In other recent news, Cellectis has made significant strides in non-viral gene editing techniques. The company published research demonstrating that circular single-stranded DNA (CssDNA) is a highly efficient template for gene insertion in hematopoietic stem and progenitor cells. This method achieved insertion rates exceeding 40%, marking a 3-5 times higher efficiency than previous techniques using linear single-stranded DNA. Additionally, Cellectis announced promising data from its Phase 1 BALLI-01 study, which evaluated lasme-cel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. The study showed an overall response rate of 68% with lasme-cel Process 2 manufacturing, increasing to 83% at the recommended Phase 2 dose. Notably, the response rate reached 100% in the target Phase 2 population. These developments highlight Cellectis’ ongoing advancements in gene editing and therapeutic applications.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Which stock should you buy in your very next trade?

AI computing powers are changing the stock market. Investing.com's ProPicks AI includes dozens of winning stock portfolios chosen by our advanced AI.

Year to date, 3 out of 4 global portfolios are beating their benchmark indexes, with 98% in the green. Our flagship Tech Titans strategy doubled the S&P 500 within 18 months, including notable winners like Super Micro Computer (+185%) and AppLovin (+157%).

Which stock will be the next to soar?